North America Metastatic Cancer Drugs Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. North America Metastatic Cancer Drugs Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. North America Metastatic Cancer Drugs Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. North America Metastatic Cancer Drugs Market Regional Analysis

6.2 North America Metastatic Cancer Drugs Market Revenue 2019-2028 (US$ Million)

6.3 North America Metastatic Cancer Drugs Market Forecast Analysis

7. North America Metastatic Cancer Drugs Market Analysis – by Cancer Type

7.1 Breast Cancer

7.1.1 Overview
7.1.2 Breast Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

7.2 Lung Cancer

7.2.1 Overview
7.2.2 Lung Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

7.3 Liver Cancer

7.3.1 Overview
7.3.2 Liver Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

7.4 Hematological Cancer

7.4.1 Overview
7.4.2 Hematological Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

7.5 Brain Cancer

7.5.1 Overview
7.5.2 Brain Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

7.6 Prostate Cancer

7.6.1 Overview
7.6.2 Prostate Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

7.7 Pancreatic Cancer

7.7.1 Overview
7.7.2 Pancreatic Cancer: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

8. North America Metastatic Cancer Drugs Market Analysis – by Route of Administration

8.1 Intravenous and Intramuscular

8.1.1 Overview
8.1.2 Intravenous and Intramuscular: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

9. North America Metastatic Cancer Drugs Market Analysis – by Drug Class

9.1 HER2 Inhibitors

9.1.1 Overview
9.1.2 HER2 Inhibitors: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

9.2 Immune Checkpoint Inhibitors

9.2.1 Overview
9.2.2 Immune Checkpoint Inhibitors: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

9.3 PARP Inhibitors

9.3.1 Overview
9.3.2 PARP Inhibitors: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

9.4 Kinase Inhibitors

9.4.1 Overview
9.4.2 Kinase Inhibitors: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

10. North America Metastatic Cancer Drugs Market Analysis – by Product

10.1 Branded

10.1.1 Overview
10.1.2 Branded: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

10.2 Generics

10.2.1 Overview
10.2.2 Generics: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

10.3 Biosimilars

10.3.1 Overview
10.3.2 Biosimilars: North America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

11. North America Metastatic Cancer Drugs Market – North America Analysis

11.1 Overview

11.2 North America

11.2.1 North America Metastatic Cancer Drugs Market Breakdown, by Key Country, 2022 and 2028 (%)
11.2.1.1 North America Metastatic Cancer Drugs Market – Revenue and Forecast Analysis – by Country
11.2.1.1 US: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.1.1 US: North America Metastatic Cancer Drugs Market Breakdown, by Cancer Type
11.2.1.1.2 US: North America Metastatic Cancer Drugs Market Breakdown, by Route of Administration
11.2.1.1.3 US: North America Metastatic Cancer Drugs Market Breakdown, by Drug Class
11.2.1.1.4 US: North America Metastatic Cancer Drugs Market Breakdown, by Product

11.2.1.2 Canada: North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.2.1 Canada: North America Metastatic Cancer Drugs Market Breakdown, by Cancer Type
11.2.1.2.2 Canada: North America Metastatic Cancer Drugs Market Breakdown, by Route of Administration
11.2.1.2.3 Canada: North America Metastatic Cancer Drugs Market Breakdown, by Drug Class
11.2.1.2.4 Canada: North America Metastatic Cancer Drugs Market Breakdown, by Product

11.2.1.3 Mexico : North America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)

11.2.1.3.1 Mexico : North America Metastatic Cancer Drugs Market Breakdown, by Cancer Type
11.2.1.3.2 Mexico : North America Metastatic Cancer Drugs Market Breakdown, by Route of Administration
11.2.1.3.3 Mexico : North America Metastatic Cancer Drugs Market Breakdown, by Drug Class
11.2.1.3.4 Mexico : North America Metastatic Cancer Drugs Market Breakdown, by Product

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 AbbVie Inc.

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 Amgen Inc.

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 Bristol-Myers Squibb Company

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 F. HOFFMANN-LA ROCHE LTD.

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 Novartis AG

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

14.6 Astrazeneca

14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments

14.7 Eli Lilly and Company

14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments

14.8 MERCK KGaA

14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments

14.9 Pfizer Inc. (Arena Pharmaceutical GmbH)

14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments

14.10 Johnson and Johnson Services, Inc.

14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

North America Metastatic Cancer Drugs Market